Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

miR17~92 restrains pro-apoptotic BIM to ensure survival of haematopoietic stem and progenitor cells.

Brinkmann K, Ng AP, de Graaf CA, Di Rago L, Hyland CD, Morelli E, Rautela J, Huntington ND, Strasser A, Alexander WS, Herold MJ.

Cell Death Differ. 2019 Oct 7. doi: 10.1038/s41418-019-0430-6. [Epub ahead of print]

PMID:
31591473
2.

Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC.

Brockwell NK, Rautela J, Owen KL, Gearing LJ, Deb S, Harvey K, Spurling A, Zanker D, Chan CL, Cumming HE, Deng N, Zakhour JM, Duivenvoorden HM, Robinson T, Harris M, White M, Fox J, Ooi C, Kumar B, Thomson J, Potasz N, Swarbrick A, Hertzog PJ, Molloy TJ, Toole SO, Ganju V, Parker BS.

NPJ Precis Oncol. 2019 Aug 29;3:21. doi: 10.1038/s41698-019-0093-2. eCollection 2019.

3.

Therapeutic blockade of activin-A improves NK cell function and antitumor immunity.

Rautela J, Dagley LF, de Oliveira CC, Schuster IS, Hediyeh-Zadeh S, Delconte RB, Cursons J, Hennessy R, Hutchinson DS, Harrison C, Kita B, Vivier E, Webb AI, Degli-Esposti MA, Davis MJ, Huntington ND, Souza-Fonseca-Guimaraes F.

Sci Signal. 2019 Aug 27;12(596). pii: eaat7527. doi: 10.1126/scisignal.aat7527.

PMID:
31455725
4.

Loss-of-Function in SMAD4 Might Not Be Critical for Human Natural Killer Cell Responsiveness to TGF-β.

Healy LP, Rossi GR, Rautela J, Slade CA, Huntington ND, Winship IM, Souza-Fonseca-Guimaraes F.

Front Immunol. 2019 May 1;10:904. doi: 10.3389/fimmu.2019.00904. eCollection 2019.

5.

Quantifying NK cell growth and survival changes in response to cytokines and regulatory checkpoint blockade helps identify optimal culture and expansion conditions.

Hennessy RJ, Pham K, Delconte R, Rautela J, Hodgkin PD, Huntington ND.

J Leukoc Biol. 2019 Jun;105(6):1341-1354. doi: 10.1002/JLB.MA0718-296R. Epub 2019 May 12.

PMID:
31079418
6.

Author Correction: Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin.

Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Effern M, McBain N, Wagner T, Edwards J, McConville R, Wilmott JS, Scolyer RA, Tüting T, Palendira U, Gyorki D, Mueller SN, Huntington ND, Bedoui S, Hölzel M, Mackay LK, Waithman J, Gebhardt T.

Nature. 2019 Feb;566(7745):E10. doi: 10.1038/s41586-019-0958-0.

PMID:
30742076
7.

Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin.

Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Effern M, McBain N, Wagner T, Edwards J, McConville R, Wilmott JS, Scolyer RA, Tüting T, Palendira U, Gyorki D, Mueller SN, Huntington ND, Bedoui S, Hölzel M, Mackay LK, Waithman J, Gebhardt T.

Nature. 2019 Jan;565(7739):366-371. doi: 10.1038/s41586-018-0812-9. Epub 2018 Dec 31. Erratum in: Nature. 2019 Feb;566(7745):E10.

PMID:
30598548
8.

Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes.

Jiao Y, Davis JE, Rautela J, Carrington EM, Ludford-Menting MJ, Goh W, Delconte RB, Souza-Fonseca-Guimaraes F, Koldej R, Gray D, Huang D, Kile BT, Lew AM, Ritchie DS, Huntington ND.

Cell Death Differ. 2019 Aug;26(8):1516-1530. doi: 10.1038/s41418-018-0228-y. Epub 2018 Nov 12.

PMID:
30420758
9.

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos.

Fedele PL, Willis SN, Liao Y, Low MS, Rautela J, Segal DH, Gong JN, Huntington ND, Shi W, Huang DCS, Grigoriadis G, Tellier J, Nutt SL.

Blood. 2018 Nov 15;132(20):2166-2178. doi: 10.1182/blood-2018-05-850727. Epub 2018 Sep 18.

PMID:
30228232
10.

GM-CSF Quantity Has a Selective Effect on Granulocytic vs. Monocytic Myeloid Development and Function.

Sun L, Rautela J, Delconte RB, Souza-Fonseca-Guimaraes F, Carrington EM, Schenk RL, Herold MJ, Huntington ND, Lew AM, Xu Y, Zhan Y.

Front Immunol. 2018 Aug 28;9:1922. doi: 10.3389/fimmu.2018.01922. eCollection 2018.

11.

Generation of novel Id2 and E2-2, E2A and HEB antibodies reveals novel Id2 binding partners and species-specific expression of E-proteins in NK cells.

Rautela J, Dagley LF, Kratina T, Anthony A, Goh W, Surgenor E, Delconte RB, Webb AI, Elwood N, Groom JR, Souza-Fonseca-Guimaraes F, Corcoran L, Huntington ND.

Mol Immunol. 2018 Aug 23. pii: S0161-5890(18)30681-3. doi: 10.1016/j.molimm.2018.08.017. [Epub ahead of print]

PMID:
30144957
12.

Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.

Baell JB, Leaver DJ, Hermans SJ, Kelly GL, Brennan MS, Downer NL, Nguyen N, Wichmann J, McRae HM, Yang Y, Cleary B, Lagiakos HR, Mieruszynski S, Pacini G, Vanyai HK, Bergamasco MI, May RE, Davey BK, Morgan KJ, Sealey AJ, Wang B, Zamudio N, Wilcox S, Garnham AL, Sheikh BN, Aubrey BJ, Doggett K, Chung MC, de Silva M, Bentley J, Pilling P, Hattarki M, Dolezal O, Dennis ML, Falk H, Ren B, Charman SA, White KL, Rautela J, Newbold A, Hawkins ED, Johnstone RW, Huntington ND, Peat TS, Heath JK, Strasser A, Parker MW, Smyth GK, Street IP, Monahan BJ, Voss AK, Thomas T.

Nature. 2018 Aug;560(7717):253-257. doi: 10.1038/s41586-018-0387-5. Epub 2018 Aug 1.

PMID:
30069049
13.

Molecular insight into targeting the NK cell immune response to cancer.

Rautela J, Souza-Fonseca-Guimaraes F, Hediyeh-Zadeh S, Delconte RB, Davis MJ, Huntington ND.

Immunol Cell Biol. 2018 May;96(5):477-484. doi: 10.1111/imcb.12045. Epub 2018 Apr 17. Review.

PMID:
29577414
14.

Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.

Duivenvoorden HM, Rautela J, Edgington-Mitchell LE, Spurling A, Greening DW, Nowell CJ, Molloy TJ, Robbins E, Brockwell NK, Lee CS, Chen M, Holliday A, Selinger CI, Hu M, Britt KL, Stroud DA, Bogyo M, Möller A, Polyak K, Sloane BF, O'Toole SA, Parker BS.

J Pathol. 2017 Dec;243(4):496-509. doi: 10.1002/path.4990. Epub 2017 Oct 31.

PMID:
29086922
15.

Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.

Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS.

Cancer Immunol Res. 2017 Oct;5(10):871-884. doi: 10.1158/2326-6066.CIR-17-0150. Epub 2017 Aug 28.

16.

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ.

Nat Immunol. 2017 Sep;18(9):1004-1015. doi: 10.1038/ni.3800. Epub 2017 Jul 31.

PMID:
28759001
17.

Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.

Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hölzel M, Scolyer RA, Smyth MJ.

Cancer Res. 2017 Sep 1;77(17):4684-4696. doi: 10.1158/0008-5472.CAN-17-0393. Epub 2017 Jun 26.

18.

Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival.

Viant C, Guia S, Hennessy RJ, Rautela J, Pham K, Bernat C, Goh W, Jiao Y, Delconte R, Roger M, Simon V, Souza-Fonseca-Guimaraes F, Grabow S, Belz GT, Kile BT, Strasser A, Gray D, Hodgkin PD, Beutler B, Vivier E, Ugolini S, Huntington ND.

J Exp Med. 2017 Feb;214(2):491-510. doi: 10.1084/jem.20160869. Epub 2017 Jan 5.

19.

IL-15 signaling in NK cell cancer immunotherapy.

Rautela J, Huntington ND.

Curr Opin Immunol. 2017 Feb;44:1-6. doi: 10.1016/j.coi.2016.10.004. Epub 2016 Nov 11. Review.

PMID:
27835762
20.

CIS is a potent checkpoint in NK cell-mediated tumor immunity.

Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM, Stannard K, Zhang JG, Teh C, Firth M, Ushiki T, Andoniou CE, Degli-Esposti MA, Sharp PP, Sanvitale CE, Infusini G, Liau NP, Linossi EM, Burns CJ, Carotta S, Gray DH, Seillet C, Hutchinson DS, Belz GT, Webb AI, Alexander WS, Li SS, Bullock AN, Babon JJ, Smyth MJ, Nicholson SE, Huntington ND.

Nat Immunol. 2016 Jul;17(7):816-24. doi: 10.1038/ni.3470. Epub 2016 May 23.

PMID:
27213690
21.

Antitumour actions of interferons: implications for cancer therapy.

Parker BS, Rautela J, Hertzog PJ.

Nat Rev Cancer. 2016 Mar;16(3):131-44. doi: 10.1038/nrc.2016.14. Review.

PMID:
26911188
22.

Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid-derived suppressor cells in breast cancer.

Edgington-Mitchell LE, Rautela J, Duivenvoorden HM, Jayatilleke KM, van der Linden WA, Verdoes M, Bogyo M, Parker BS.

Oncotarget. 2015 Sep 29;6(29):27008-22. doi: 10.18632/oncotarget.4714.

23.

Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer.

Rautela J, Baschuk N, Slaney CY, Jayatilleke KM, Xiao K, Bidwell BN, Lucas EC, Hawkins ED, Lock P, Wong CS, Chen W, Anderson RL, Hertzog PJ, Andrews DM, Möller A, Parker BS.

Cancer Immunol Res. 2015 Nov;3(11):1207-17. doi: 10.1158/2326-6066.CIR-15-0065. Epub 2015 Jul 21.

24.

Bone specific immunity and its impact on metastasis.

Baschuk N, Rautela J, Parker BS.

Bonekey Rep. 2015 Apr 15;4:665. doi: 10.1038/bonekey.2015.32. eCollection 2015. Review.

25.

BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity.

Cao Y, Slaney CY, Bidwell BN, Parker BS, Johnstone CN, Rautela J, Eckhardt BL, Anderson RL.

Cancer Res. 2014 Sep 15;74(18):5091-102. doi: 10.1158/0008-5472.CAN-13-3171.

26.

The emerging role of immunosurveillance in dictating metastatic spread in breast cancer.

Slaney CY, Rautela J, Parker BS.

Cancer Res. 2013 Oct 1;73(19):5852-7. doi: 10.1158/0008-5472.CAN-13-1642. Epub 2013 Sep 23. Review.

Supplemental Content

Loading ...
Support Center